menu
    • menu
    [{"orgOrder":0,"company":"CEL-SCI","sponsor":"Aegis Capital Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"Interleukin 2","moa":"T Cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Aegis Capital Corp","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Aegis Capital Corp"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Interleukin 2","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Not Applicable"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Interleukin 2","moa":"Il-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clinigen Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Clinigen Group \/ Not Applicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Interleukin 2","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Not Applicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Financing","leadProduct":"Interleukin 2","moa":"T Cell","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"CEL-SCI \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Undisclosed"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Venrock Healthcare Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"AB-101","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ Venrock Healthcare Capital","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ Venrock Healthcare Capital"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Avacopan","moa":"C5aR receptor","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Interleukin-2","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Iovance Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Fludarabine","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genocea \/ Not Applicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Fludarabine","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genocea \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genocea \/ Not Applicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Interleukin-2","moa":"TNF-13","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Not Applicable"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AB-101","moa":"ADCC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Artiva Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Noventia Pharma","sponsor":"Delbert Lab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Histamine Dihydrochloride","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Noventia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Noventia Pharma \/ Delbert Lab","highestDevelopmentStatusID":"12","companyTruncated":"Noventia Pharma \/ Delbert Lab"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Interleukin 2","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coya Therapeutics \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Coya Therapeutics \/ Dr. Reddy's Laboratories"}]

    Find Clinical Drug Pipeline Developments & Deals for Pegilodecakin

    Menu

    Pegilodecakin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Coya Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Coya Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interleukin 2,Abatacept

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Dr. Reddy\'s Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development a...

                            Details : Under the agreement, Coya granted Dr. Reddy’s an exclusive license to commercialize COYA 302, a proprietary co-pack kit containing combination of low dose interleukin-2 and CTLA-4 Ig (abatacept) for the treatment of Amyotrophic Lateral Sclerosis.

                            Brand Name : COYA 302

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 06, 2023

                            Lead Product(s) : Interleukin 2,Abatacept

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Dr. Reddy\'s Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Noventia Pharma

                            Italy arrow
                            CPhI India 2024
                            Not Confirmed

                            Noventia Pharma

                            Italy arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Histamine Dihydrochloride,Interleukin 2

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Delbert Lab

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            DELBERT Laboratories Are Proud to Announce the Acquisition From Noventia Pharma Srl of the European Marketing ...

                            Details : Ceplene® demonstrated a clinical interest in maintenance treatment of acute myeloid leukemia (AML) in patients below 60 years of age in first "complete remission" (symptom-free period of disease after initial treatment) in a clinical study.

                            Brand Name : Ceplene

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 18, 2022

                            Lead Product(s) : Histamine Dihydrochloride,Interleukin 2

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Delbert Lab

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-101,Rituximab,Interleukin 2

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Artiva Announces AB-101 Abstract Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2022 ...

                            Details : AB-101, an ADCC enhancer NK-cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers. Artiva is currently advancing a Phase 1/2 of AB-101 in combination with rituximab for the treatment of relapsed or refractory B-...

                            Brand Name : AB-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 05, 2022

                            Lead Product(s) : AB-101,Rituximab,Interleukin 2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            RemeGen

                            China arrow
                            CPhI India 2024
                            Not Confirmed

                            RemeGen

                            China arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telitacicept,Interleukin 2

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemi...

                            Details : Preliminary results from the full analysis set (FAS) showed that at week 52, patients who received RC-18 (telitacicept) had a significantly higher rate of SRI-4 (The Systemic Lupus Erythematosus Responder Index 4) response than those who received placebo...

                            Brand Name : RC-18

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 19, 2022

                            Lead Product(s) : Telitacicept,Interleukin 2

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Genocea

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Genocea

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GEN-011,Interleukin 2,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022

                            Details : GEN-011 is a neoantigen-targeted peripherally derived T cell therapy candidate comprised of autologous CD4+ and CD8+ T cells that are specific for up to 30 ATLAS-identified neoantigens to limit tumor escape.

                            Brand Name : GEN-011

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 08, 2022

                            Lead Product(s) : GEN-011,Interleukin 2,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Genocea

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Genocea

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GEN-011,Interleukin 2,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting

                            Details : GEN-011 is a neoantigen-targeted peripherally derived T cell therapy candidate comprised of autologous CD4+ and CD8+ T cells that are specific for up to 30 ATLAS-identified neoantigens to limit tumor escape.

                            Brand Name : GEN-011

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 08, 2022

                            Lead Product(s) : GEN-011,Interleukin 2,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Iovance Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Iovance Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IOV-2001,Interleukin 2

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Iovance Biotherapeutics to Present at Upcoming Conferences

                            Details : IOV-2001, non-Genetically Modified Autologous PBL product, showed activity against autologous leukemia cancer cells in preclinical studies is now under investigation in the treatment of CLL or SLL.

                            Brand Name : IOV-2001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 07, 2021

                            Lead Product(s) : IOV-2001,Interleukin 2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Amgen Inc

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Amgen Inc

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avacopan,Interleukin 2

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ChemoCentryx Announces Results of FDA Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis

                            Details : The Committee voted on three questions presented by the FDA on whether the efficacy data support approval of avacopan for the treatment of adult patients with AAV, safety profile of avacopan and benefit-risk profile of the product.

                            Brand Name : CCX168

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 06, 2021

                            Lead Product(s) : Avacopan,Interleukin 2

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Artiva Biotherapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AB-101,Rituximab,Interleukin 2

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Venrock Healthcare Capital

                            Deal Size : $120.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Artiva Raises $120M in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies

                            Details : Artiva’s pipeline includes AB-101, an ADCC enhancer NK-cell therapy which is currently under Phase 1/2 clinical trial in combination with rituximab for the treatment of relapsed or refractory B-cell lymphomas.

                            Brand Name : AB-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 26, 2021

                            Lead Product(s) : AB-101,Rituximab,Interleukin 2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Venrock Healthcare Capital

                            Deal Size : $120.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            CEL-SCI

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            CEL-SCI

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interleukin 2

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $10.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            CEL-SCI Corporation Receives $10 Million Through Warrant Exercises

                            Details : These funds will allow the Company to complete the expansion of its Multikine* (Leukocyte Interleukin, Inj.) cancer immunotherapy manufacturing facility near Baltimore, MD in anticipation of BLA submission and subsequent marketing approval.

                            Brand Name : Multikine

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 30, 2020

                            Lead Product(s) : Interleukin 2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $10.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth